Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-YANG Influenza Vaccine in Healthy Adults
NCT02154308Phase 3Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Nov 2012
- Primary completion
- Mar 2013
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Ilyang Flu Vaccine in influenza, sponsored by Il-Yang Pharmaceutical. Primary endpoints: Solicited local & general Adverse Event, Unsolicited Adverse Event at Day 28, Percentage of subjects achieving seroconversion for HI antibody at Day 28 and 1 more. Started Nov 2012; status: completed.
02
Drugs
Ilyang Flu Vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02154308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02154308.